Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fundamentally nothing has changed with regards to experiments, licensing etc. Yes they still need funding. What change is the stupid way Koos did this. Having no good news event to back it up is pure business malpractice. I have seen splits in growth companies go extremely well. For what it's worth it looks way oversold now, especially the preferred.
Good news before the split is critical. Difference between a great move and a crap move.
I doubt too much shorting here. Maybe look at the $30M in convertible notes being issued. Only the first tranche of 10M is issued with 20M soon to go. This will Balloon the OS and float.
This may have pops but gonna be depressed prices for awhile. Could easily see two's or lower. I'll wait.
Good bet long term if you have the patience.
Thanks for the vid. Need to spend some of that $30M on a wifi extender. Also as a Nasdaq CEO try to proof it before publishing.
Like what they're doing here.
Would have much rather he had issued those shares reducing debt. Not going to judge for now, every public company needs PR so if you don't want to spend cash......
You certainly have a low bar for a pump. Besides the fact your the biggest poster here.
Good part of the presentation focused on the debt. The elimination of dilutive debt will result in higher share price which gives them more room to maneuver. As per Lander current science testing will end late February so minimal updates till then unless on the debt front.
Elimination of debt also brings the note holder with their large share count back on the side of value.
Been around Regen awhile and of late there is much better resolve towards gaining value with their science.
Good luck !!!
You are more right than you think. Same note holders took it from .0001 to 8c. They have used csti, gstm and otcx to control the price for conversion for years.
Several months back Koos gave them hundreds of millions in shares to write off a large portion of debt. They won't sell down here. Unfortunately not sure where the remainder of the converts lie at this point. They'll move it on big news so we also have to wait for that.
Okay I went back and watched the whole video and actually once you get past the initial cringe segment there's plenty of info to digest. Probably their most informative yet.
Haha.......... If all weak hands need to exit before a rally starts then that video should do it.
Obvious manipulation. Snuff out any potential interest immediately. It's a common OTC practice
You astutely pointed out Rossi's problem. Not much set in concrete. Why would a client commit when the product is not really in production. I totally agree that may change when the factory is up and running.
Great opportunity but end users pay the bills and not many of them yet. Company is coming to a pivot point next couple quarters.
They became compliant with the SEC. Facts ARE stubborn things !!!
I can read a chart, thank you.
You answered the first "allegedly" with another of my affiliation with this company. I have none, nothing, nada to do with this company. I will watch the note. Total destruction of a company is not in the interest of the note holder. Figure it out from there.
So no more rabbit holes please, provide back up if you have any.
While I'm not a fan of OTC practices "allegedly" is the same as rumors and has no place on any board until it is fact. Please produce back up.
There is plainly fear mongering on this ticker. Fact!
I don't own it but big profit can be made following noteholders. Watching
Tesla just announced a hiring freeze and first quarter layoffs. Not sure why you are attaching worksport to Tesla.
I'm also bullish on this company but being patient about jumping back in. Rossi's rosy picture is a lot slower in reality. All about profits eod.
I can tell you they they are already in talks about their newest cell exhaustion program which is in the testing lab. This will be a cash cow for them and its probably a couple months out.
Clean up the debt and then look out........
When small bio's announce licensing, partnership deals, approvals, clearing debt etc. Their share price jumps like no other. By the time "something" happens most of the great price value has passed.
Only scared money will wait for "something" to happen.
But good luck anyway.
Sold this at 39 cents pre-split, wasn't sold on Rossi's plan. He's a salesman who's been selling hype and until he starts delivering actual sales then the ticker will struggle.
I'll wait. Who know, I may get it back for 39 cents.
Took awhile but it seems he's admitting the damage this toxic debt is doing. Science results are not far off and that will create licensing and begin positive loops.
Clear the debt and we move. IMO
So many CEO's rolls the dice with convertibles. They all succumb to ballooning share count crashing share price and eventually a worthless company. Probably headed to trips.
Bring up the next sucker CEO.
Business as usual for the SEC. Go after small fish and make headlines on the impression they protect the investor. Meanwhile the Goldman sac's of the world slap buy ratings on companies while simultaneously shorting them and the SEC doesn't bat an eyelid.
You would be hard pressed to find an OTC stock that rallies year end. Best we can hope is to clean up the debt.
With the quality of their advisory board I would not be surprised (and would like) to see a essay on their approach. Would be great for the company and investors alike.
Nothing legitimizes your program and science like world renowned Peers hopping aboard. Will make licensing so much easier which is only a matter of time. Licensing creates income which pays for more testing and thus more deals and starts a positive loop.
Koos has cleaned up a lot of debt, however I am hoping it's eliminated before any future announcements. We're getting close.
Correct!!!!!
It's actually hilarious what a cesspool of corruption the OTC is but then they throw out a few requirements to try and legitimize their platform. Wouldn't worry to much about that letter.
Would appreciate a run though. Seems very undervalued.
Maybe an update on science but these are not intended as press releases. I'll keep my anticipation's low.
Business banks are constantly scouring for deals to make either in buyouts or partnerships. Presentations are small companies way of trying to get noticed by other Pharma and investment companies. Business head hunters.
Regen is trying to get noticed.
Nor would he refuse it.
Merely pointing to the acquisitions and the dollars involved.
Top five biopharma buyout so far in 2021
Buyer . Target . Price
CSL Vifor. $11.7bn
Merck Acceleron Pharma. $11.5bn
Jazz GW Pharmaceuticals. $7.2bn
Pfizer . Arena. $6.7bn
Novo Nordisk. Dicerna . $3.3bn
A slew of Big Pharma suitors could be looking to buy Mirati Therapeutics (MRTX), according to reports that sent MRTX stock close to a breakout Wednesday.
Bloomberg reported Tuesday that Mirati has drawn takeover interest ahead of a key data readout next month. Potential buyers include Pfizer (PFE), Merck (MRK), Bristol Myers Squibb (BMY) and AstraZeneca (AZN).
Mirati is working on a number of cancer treatments. But of key investor interest is its non small-cell lung cancer efforts. The company is working on a treatment for patients with a mutation in their KRAS gene.
On today's stock market, MRTX stock surged 11.3% to 95.85. That followed a 15.5% pop on Tuesday. Shares narrowly broke out of a cup base with a buy point at 95.79, according to MarketSmith.com.
MRTX Stock: Rivaling Amgen's Approved Drug
Mirati is already working on launch preparation for adagrasib, its potential lung cancer treatment. The FDA is expected to decide whether to approve adagrasib by Dec. 14. Also next month, Mirati will unveil the results of adagrasib plus Merck's Keytruda in previously untreated lung cancer patients.
Amgen's (AMGN) Lumakras also targets the same mutation in the KRAS gene. These mutations have close ties to cancer and have, historically, been difficult to target. Lumakras has now been on the market for over a year.
"We think an adagrasib approval is more likely than not, at which point the label is likely to be heavily scrutinized, as investors will compare it to Lumakras' label to determine the competitive profile of the new entrant into the market," SVB Securities analyst Andrew Berens said in a recent report.
He has an outperform rating on MRTX stock.
Mirati declined to comment on the speculation.
"We are driven by the desire to improve patient outcomes and are actively looking forward to several upcoming critical company milestones including the potential approval of adagrasib for patients with NSCLC with a KRAS G12C mutation," a Mirati spokesman said in an email.
MRTX stock has a strong Relative Strength Rating of 85, according to IBD Digital. This puts shares in the top 15% of all stocks in terms of 12-month performance.
That is actually very cool.
Rhetoric kicked up a notch couple days ago. Selling started several hours before the 8k was released. Smells of convertibles again. Probably time is short till FDA approvals so noteholder on the move.
Agreed but partnership is for phase 3 development and commercialization. Licensing deals are totally different and can and in my opinion will become a nice revenue source to fund phases 1 and 2.
Also they are applying for (and likely to get) fast track. Might not be the grind you think.
Good Luck!
After watching the presentation your point comes back to me. Everything in the body is connected. Same micro biome in your gut is found in the brain. Liver takes care of your extremities etc.
As Lander said, scientists are not sure what NR2F6 checkpoint does so that discovery might be huge. Another company may discover its secrets which make all those patent so valuable to maintain.
They're plodding along nicely.
Convertibles........The kiss of death.
Convertibles........The kiss of death.
More analysts are now pointing to a market reversal after the mid terms regardless of Fed. Definitely some bio's starting some moves. Good timing on the sector.
Hoping Koos has some good news on Wednesday and maybe move with the start of any potential rally. Leading sectors at the beginning of a rally outperform all other sectors substantially.
Couldn't agree more. They have a lot going on but it's their new cell exhaustion program that is currently in testing that I believe will be the springboard to licensing and partnership dollars and fund their mRNA program.
Read recently that there is literally a global race to unlock the potential of mRNA in all diseases. They are in a good spot, just need a few dollars to keep it rolling. Lets see what this seminar brings.